Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Long-Term Investments (2024 - 2025)

Stoke Therapeutics has reported Long-Term Investments over the past 2 years, most recently at $106.3 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $106.3 million for Q4 2025, up 256.29% from a year ago — trailing twelve months through Dec 2025 was $106.3 million (up 256.29% YoY), and the annual figure for FY2025 was $106.3 million, up 256.29%.
  • Long-Term Investments for Q4 2025 was $106.3 million at Stoke Therapeutics, up from $80.3 million in the prior quarter.
  • Over the last five years, Long-Term Investments for STOK hit a ceiling of $107.3 million in Q2 2025 and a floor of $23.0 million in Q1 2025.